Charles River Laboratories (CRL) Tops Q1 EPS by 21c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $334.72 -4.87%
Financial Fact:
Income from continuing operations, net of tax: 37.69M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Income from continuing operations, net of tax: 37.69M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q1 EPS of $2.27, $0.21 better than the analyst estimate of $2.06. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $992.31 million.
GUIDANCE:
Charles River Laboratories sees FY2024 EPS of $10.90-$11.40, versus the consensus of $11.02.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Charles River Laboratories (CRL) Tops Q3 EPS by 12c ; Offers Guidance
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Marriott Vacations Worldwide (VAC) Tops Q3 EPS by 7c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
